NCT01241422 is a Phase 2 clinical trial of JNJ 40929837 in Asthma, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

Who is sponsoring NCT01241422?

NCT01241422 is sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C..

What drugs are being tested in NCT01241422?

Interventions in NCT01241422: JNJ 40929837, Placebo, Montelukast.

Is NCT01241422 still recruiting?

NCT01241422 is currently completed. Last updated 18 December 2015.

Last reviewed 2015-12-18 · How we verify

NCT01241422

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Efficacy of JNJ 40929837 for the Treatment of Asthma Using a Bronchial Allergen Challenge Model

Completed Phase 2 Last updated 18 December 2015

What this trial tests

Phase 2 trial testing JNJ 40929837 in Asthma in 22 participants. Completed in 1 June 2011.

Timeline

1 November 2010

Primary endpoint
1 June 2011

1 June 2011

Quick facts

Lead sponsor	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	quadruple
Primary purpose	treatment
Enrollment	22
Start date	1 November 2010
Primary completion	1 June 2011
Estimated completion	1 June 2011
Sites	2 locations across Germany, United Kingdom

Drugs / interventions tested

JNJ 40929837 — full drug profile →
Placebo
Montelukast (montelukast) — full drug profile →

Conditions studied

Asthma — all drugs for Asthma →

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. — full company profile →

Who can join

Adults 18 to 55, any sex, with Asthma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Change in forced expiratory volume in 1 second (FEV1) during the late response to allergen
Time frame: 3 to 10 hours after allergen exposure on Day 6 of each treatment period

Sponsor's own description

The purpose of this study is to evaluate the allergen-induced late asthmatic response (LAR), as measured by maximal percent fall in forced expiratory volume in 1 second, in participants with stable mild atopic asthma after treatment with JNJ 40929837 as compared to placebo.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma.
Barchuk W, Lambert J, Fuhr R, Jiang JZ, et al · · 2014 · cited 19× · PMID 25018015 · DOI 10.1016/j.pupt.2014.06.003

Verify or expand the search:

Other recruiting trials for Asthma

Currently open trials in the same condition.

NCT07525375 — A Phase II Study to Investigate Lung Function With 2 Different Doses of Inhaled Glycopyrronium Taken With BFF Compared t · Phase 2 · recruiting
NCT07536256 — Community Connections Through Native Hawaiian Cultural Values to Strengthen Youth Resilience, Health, and Well-Being · NA · recruiting
NCT07556159 — A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice · recruiting
NCT07282886 — VENTURI (VENTilation Using Respiratory Imaging) · Phase 2 · recruiting
NCT07433569 — A Study to Investigate How Budesonide and Formoterol Move Through the Body (Pharmacokinetics) When Delivered With Differ · Phase 1 · recruiting

Other Johnson & Johnson Pharmaceutical Research & Development, L.L.C. trials

Trials by the same sponsor.

NCT04330248 — A Study of Steady-state Carbamazepine on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants · Phase 1 · completed
NCT01094262 — A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthrit · Phase 2 · terminated
NCT01060254 — A Study to Evaluate the Pain Relieving Effects, Safety, and Tolerability of JNJ-42160443 for the Relief of Bladder Pain · Phase 2 · terminated
NCT00973141 — A Dose-ranging Study of the Safety and Effectiveness of JNJ-42160443 as add-on Treatment in Patients With Osteoarthritis · Phase 2 · terminated
NCT01756404 — Study to Assess the Pharmacokinetics, Pharmacodynamics, and Safety of Canagliflozin (JNJ-28431754) in Otherwise Healthy · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01241422 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Last refreshed: 18 December 2015

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01241422.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing